
Medicine and Health
Extended-release ketamine tablets for treatment-resistant depression: a randomized placebo-controlled phase 2 trial
P. Glue, C. Loo, et al.
This multicenter trial by Paul Glue and colleagues explored the effectiveness of extended-release ketamine tablets (R-107) for treatment-resistant major depression. Results showed significant improvement in depressive symptoms, particularly in the 180 mg group, while maintaining excellent tolerability. Experience minimal side effects like headaches and dizziness, and discover how R-107 is paving a new path in depression treatment.
Playback language: English
Related Publications
Explore these studies to deepen your understanding of the subject.